As bstract. Adult T cell leukemia (ATL) and Sezary leukemia are malignant proliferations of T lymphocytes that share similar cell morphology and clinical features. ATL is associated with HTLV (human T cell leukemia/lymphoma virus), a unique human type C retrovirus, whereas most patients with the Sezary syndrome do not have antibodies to this virus. Leukemic cells of both groups were ofthe T3, T4-positive, T8-negative phenotype. Despite the similar phenotype, HTLV-negative S&ary leukemic cells frequently functioned as helper cells, whereas some HTLV-positive ATL and HTLV-positive Sezary cells appeared to function as suppressors of immunoglobulin synthesis. One can distinguish the HTLVpositive from the HTLV-negative leukemias using a monoclonal antibody (anti-Tac) that appears to identify the human receptor for T cell growth factor (TCGF). Resting normal T cells and most HTLV-negative Sezary cells were Tac-negative, whereas all ATL cell populations were Tac-positive. The observation that ATL cells manifest TCGF receptors suggests the possibility that an abnormality of the TCGF-TCGF receptor system may partially explain the uncontrolled growth of these cells.
Introduction
In normal individuals, circulating T cells represent a complex mixture of cells with different and at times opposing functions. Leukemic T cells from humans frequently represent expansions of a single clone of T cells that may retain a single immunoregulatory function. The examination of such neoplastic T cells and their soluble products in functional assays has provided valuable insights into the regulatory network of cells that control the human immune response in general and control B cell maturation and immunoglobulin production in particular (1) (2) (3) . Furthermore, the use of monoclonal antibodies to T cell surface antigens has permitted useful correlations between cell function and phenotype (4) (5) (6) (7) (8) (9) .
In the present studies we examined leukemias of mature T cells. The first form, the Sezary syndrome, is characterized by exfoliative erythroderma, generalized lymphadenopathy, and circulating pleomorphic malignant T lymphocytes that have a propensity for epidermal infiltration. The second leukemia, the adult T cell leukemia (ATL)', was recently described by Uchiyama et al. (10) . ATL is also a malignancy of mature T cells that has a tendency to infiltrate the skin. However, certain clinical features aid in distinguishing these syndromes. First, ATL has a more aggressive course and is often complicated by hypercalcemia and pulmonary infiltrates. The median survival is generally 1 yr or less (10, 1 1) . Second, cases of ATL are clustered geographically, occurring in the southwest of Japan, the Carib-I. Abbreviations used in this paper: ATL, adult T cell leukemia; FACS, fluorescence-activated cell sorter; HLA, human leukocyte antigen; HTLV, human T cell leukemia/lymphoma virus; PWM, pokeweed mitogen; TCGF, T cell growth factor. bean basin, and in certain areas of the southeastern U. S. (1 1, 12) . Recently, a unique human type C retrovirus, human T cell leukemia/lymphoma virus (HTLV), has been isolated from the neoplastic T cells of patients with ATL in multiple areas of the world (13) (14) (15) (16) (17) (18) (19) . This virus was distinguished from other mammalian retroviruses by assays of nucleic acid homology and immunological assays of viral proteins. In a wide survey of human sera for antibodies to HTLV, nearly all serum samples from patients with ATL contained antibodies recognizing the core p19 and p24 proteins of this virus (20, 21) . Furthermore, up to 15% of normal donors in endemic areas of Japan and the Caribbean basin had antibodies to these core proteins. In contrast, <1% of normal donors from nonendemic areas of the world have demonstrable antibodies to HTLV. Similarly, only 2 of 245 (0.8%) patients with the Sezary syndrome, or mycosis fungoides, had serum antibodies recognizing HTLV (22) .
In the present study, we compare the immunoregulatory function and cell surface phenotype of the leukemic cells from 10 patients with the clinical diagnosis of ATL and three patients with the Sezary leukemia who had circulating antibodies to HTLV, with the function and cell surface phenotype of leukemic cells from 10 patients with the Sezary syndrome who lacked serum antibodies to HTLV.
Methods
Patient population. T cells were studied from 17 normal individuals, 10 patients with the Sezary syndrome who did not have serum antibodies to HTLV, three patients with the Sezary syndrome who had serum antibodies to HTLV, and 10 patients with the ATL. The patients with the clinical presentation of the Sezary syndrome had exfoliative erythroderma, lymphadenopathy, and a white blood cell count ranging from 12,600 to 124,000 cells/mm3. With the exception of the one patient with a total white blood cell count of 12,600, all patients had >30,000 white blood cells/mm3. All of the patients were from the U. S. and had a mean age of 62. Nine of the 10 patients without antibodies to HTLV were white, while one was black. The patients with ATL had skin involvement, usually in the form of plaquelike lesions, and had white blood cell counts that ranged from 11,200 to 105,000/mm3. Three of these patients had a white blood cell count of between 1 1,000 and 20,000/mm3. Six ofthe patients were hypercalcemic. Three ofthe patients were Oriental (residing in Japan), eight were black, and one was white. One of these latter nine patients was from the Caribbean while the remainder resided in the U. S. (23) . We also determined the reactivity of the leukemic cell populations with a monoclonal antibody of the IgG2a class termed anti-Tac prepared in our laboratory (8, 24) that reacts with the human receptor for T cell growth factor (TCGF) (9, 25) .
Immunofluorescence analysis ofcells with thefluorescence-activated cell sorter (FACS). The cells were analyzed by using immunofluorescence and FACS analysis with monoclonal antibodies by a slight modification of a procedure described previously (26 Assays for helper or suppressor cell activity. The methods used to test for immunoglobulin biosynthesis and for helper and suppressor activity using the PWM-driven immunoglobulin biosynthesis system have been described in detail previously (1, 2, 27, 28) . PWM-stimulated B cells in the absence of T cells produce very small amounts of immunoglobulin (1, 28, 29 were used in these co-culture studies. The immunoglobulin synthesis in these co-cultures was compared with that predicted from the determinations of the immunoglobulin synthesis by the PWM-stimulated indicator population and leukemic cell populations when cultured alone. The amount of immunoglobulin produced and secreted into the media after 12 d in culture in the biosynthesis studies discussed above was determined by heavy chain specific double antibody radioimmunoassays, as previously described (27) . Assaysfor antibodies to HTL V. The sera of patients with the Sezary syndrome and ATL in the present study were analyzed for antibodies to the core proteins p19 and p24 of HTLV using solid-phase radioimmunoassays, as previously described (20, 21) .
Results
The capacity ofperipheral blood mononuclear cells from patients with the Sezary syndrome, ATL, and normal individuals to synthesize IgG, IgA, and IgM was evaluated using the in vitro PWM-stimulated immunoglobulin biosynthesis system. The 17 normals studied synthesized geometric means of 3,147 ng (2.9)2 for IgG, 2,289 ng (2.54) for IgA, and 3,676 ng (2.57) for IgM per two million cells in culture. In contrast, none ofthe peripheral blood mononuclear cell populations from the patients with the Sezary syndrome or the ATL synthesized biologically meaningful quantities of immunoglobulin of any class when stimulated by PWM (Fig. 1) . The PWM-activated in vitro biosynthesis system was also used to determine whether the neoplastic T cells manifested helper activity when co-cultured with rigorously T celldepleted B cells from normal individuals. The approach takes advantage ofthe fact that PWM stimulation ofimmunoglobulin synthesis has an absolute requirement for helper T cells (1, 28, 29) . When normal B cells were co-cultured with either autologous or allogeneic normal T cells and PWM, they matured into immunoglobulin synthesizing and secreting cells (Fig. 1 ). In the present study, purified PWM-stimulated, normal B cells did not synthesize immunoglobulin molecules when cultured alone. However, they synthesized and secreted from 250 to over 5,000 ng of IgM when cultured with Sezary leukemic T cells of six of the nine patients studied, at a ratio of 5 X 04 Sezary cells to 5 X 105 normal B cells in culture (Fig. 1) . The synthesis of IgG and IgA in these co-cultures was comparable (data not shown). Thus, the leukemic cells of many but not all of the patients with the anti-HTLV antibody-negative Sezary syndrome functioned as helper T cells for normal B cell maturation and immunoglobulin synthesis. In contrast, the ATL cells and the leukemic cells from the three Sezary syndrome patients who had antibodies to HTLV did not manifest helper cell activity for B cell maturation and immunoglobulin synthesis (Fig. I) .
In order to determine whether the leukemic cell populations had suppressor cell activity, circulating mononuclear cells from the patients were cultured with PWM-stimulated indicator populations comprised of unseparated peripheral blood mononuclear cells from normal subjects or equal numbers of normal B cells and normal irradiated T cells (2,000 rad). In control cultures, the mean values for the production of IgG, IgA, and IgM by 10 patients with HTLV antibody-negative Sezary leukemia studied manifested suppressor cell activity (Fig. 1) . In contrast, the leukemic cells of five of the nine patients with ATL suppressed immunoglobulin synthesis when co-cultured with indicator populations of equal numbers of normal B cells and irradiated normal T cells (Fig. 1) Over the past few years there have been major advances in the correlation of the cell surface antigens of leukemic T cells identified by monoclonal antibodies with the immunoregulatory function of these cells (4-6). However, the T3, T4, and T8 monoclonal antibodies were not of value in differentiating HTLV-negative Sezary leukemic cells, which appear to manifest helper activity from either ATL cells or the S6zary leukemic cells from the three patients with serum antibodies to HTLV that appear to manifest suppressor activity. In general, both of these groups of leukemic cells bore the T3 antigen associated with mature T cells and the T4 antigen that has usually been associated with helper/induced T cell activity, whereas neither ofthe leukemic cell populations manifested the T8 antigen that is usually associated with suppressor/cytotoxic activity (Fig. 2) .
We then examined these leukemic cell populations using monoclonal antibodies to a series of activation antigens, including the T9 antigen, which defines the transferrin receptor (7), the la antigen (using the DA2 monoclonal), present on resting B cells, monocytes, and on activated T cells, the T10 antigen, which is present on primitive hemopoietic cells, thymocytes, NK cells, and on activated T cells (30) , and the Tac antigen, an antigen that recognizes the TCGF receptor on activated T cells (8) . Both T9 and Ia antigen were present on the leukemic cells ofthe majority ofpatients with either the HTLVpositive ATL or the Sezary T cell leukemias, that had no serum antibodies to HTLV, but were not present on normal resting T cells (Fig. 3) . Thus, these monoclonal antibodies help to identify both of these groups of leukemic cells as activated, rapidly proliferating cells, but they are not of value in differentiating these leukemias from each other. The monoclonal antibody TlO was ofgreater value in differentiating these leukemias. The 10 HTLV antibody negative S6zary leukemic cell populations had reduced proportions of TlO cells, whereas 10 of 1 1 HTLVpositive ATL or S6zary leukemic populations examined had normal or elevated proportions of TlO-positive T cells. The monoclonal antibody, anti-Tac, which was developed in our laboratory, appears to react with the membrane receptor for TCGF (8, 9, 25) . The anti-Tac monoclonal was of value in differentiating cells from the patients with ATL and from the three Shzary patients with antibodies to HTLV from the cells ofthe remaining Shzary patients, who were anti-HTLV antibodynegative. Nine of the ten Sezary leukemic T cell populations from patients that did not have antibodies to HTLV were Tac antigen-negative, whereas all ofthe leukemic T cell populations from patients with antibodies to HTLV were Tac antigen-positive (Fig. 4) . Thus, the HTLV-associated mature T leukemia cells were Tac antigen-positive, and thus presumably manifest the receptor for TCGF. This conclusion has been verified by showing that these same cells proliferate in the presence of TCGF. cells from both groups of patients bear a similar surface phenotype when analyzed with T3, T4, and T8 monoclonal antibodies. There are, however, certain characteristics which, when present (e.g., a tendency for the ATL patients to develop hypercalcemia), aid in distinguishing these leukemias from each other (10) (11) (12) . ATL has a definite geographical clustering, and virtually all patients have serum antibodies to HTLV. HTLV has been isolated from the leukemic cells of such patients (22) . In contrast, only 2 of 245 patients with the cutaneous T cell lymphomas, including mycosis fungoides and the Sezary syndrome, had circulating antibodies to the p1 9 and p24 core proteins of HTLV (22) . In the present study, three patients with antibodies to HTLV carried the diagnosis of Sezary syndrome on the basis of clinical features, and HTLV was isolated from their leukemic cells (18) . These patients were included with the ATL patients in our analysis, since the Sezary leukemia cells from patients with antibodies to HTLV manifested suppressor function and the Tac-positive phenotype, thus presenting a similar picture to that of the HTLV-associated ATL patients.
There were major differences demonstrable between the HTLV antibody positive T cell leukemias and the HTLV antibody-negative Sezary T cell populations when their immunoregulatory function was assessed using an in vitro immunoglobulin biosynthesis system. In the present study, six of the nine HTLV antibody-negative Sezary T cell leukemic populations function as helper cells when co-cultured with normal B cells in the presence of PWM. This observation is in accord with our previous report that some, but not all, Sezary T cell leukemic populations are dedicated to helper interactions with B lymphocytes, which facilitates B cell proliferation, maturation, and immunoglobulin synthesis (1) . Our initial observation has been confirmed by other workers (31) studying similar cell populations, although two cases of a Sezary leukemia functioning as a suppressor cell have been reported (32, 33) . These latter cases were reported before the discovery of either ATL or HTLV.
The ATL cells studied contrast with the HTLV-negative Sezary leukemic cells, in that they did not manifest helper activity in any case. However, in 6 of the 10 cases of ATL studied and in the three cases of HTLV-associated Sezary syndrome, the leukemic cells functioned as suppressor cells and inhibited the immunoglobulin synthesis of co-cultured, PWM-stimulated, normal mononuclear target cell populations. This observation is in accord with previous studies with this form of leukemia (34) . Such an apparent suppressor activity could occur in vitro through a number of mechanisms. First, leukemic T cells with receptors for TCGF have the potential to absorb TCGF from the media, leading to inhibition of T cell-dependent immunoglobulin synthesis. Second, the leukemic T cells could theoretically act as inducer T cells and activate normal precursors ofsuppressor cells into suppressor effectors. Third, HTLV could conceivably act on B cells directly to inhibit their function. Finally, the leukemic T cells could function as effectors of suppression. In terms of the first alternative, we have added 250 ng of purified TCGF to the co-cultures of 106 leukemic and 106 indicator cells without affecting the 75% inhibition of immunoglobulin synthesis observed in these co-cultures. Since this quantity of TCGF is 10-to 100-fold greater than that required to saturate the TCGF receptors on the ATL cells, it is unlikely that absorption of TCGF is the cause of the apparent suppression. In terms of the second alternative, in the present study, the leukemic T cells from individuals with a suppressor leukemia inhibited target B cells and irradiated T cells or target B cells and T8 cell-depleted T cell populations. These observations make less likely the possibility that the leukemic T cells induce a cell among the normal T cells to become the effectors of suppression. It is still possible that the leukemic cells induced T8-positive cells, contaminating the leukemic cells to become the effectors of suppression. We have made one experimental observation that argues against this alterative as well as against the possibility that leukemic cells absorb TCGF. We have established a long-term TCGF-dependent line from the Tac . I activated cord blood T cells. Furthermore, doubly banded purified HTLV did not inhibit immunoglobulin synthesis, whereas a culture supernatant from a transformed cord T cell line that was HTLV nonproducing inhibited immunoglobulin synthesis in the in vitro co-culture system. Thus, in contrast to the helper immunoregulatory function of T3+T4+T8-leukemic T cells from some patients with the Sezary syndrome, certain patients with ATL with the same phenotype have malignant T cells that appear to be cells of the suppressor T cell network. It appears from these studies, as well as from more extensive analyses from other laboratories (36) (37) (38) , that the cells defined by the T4 and T8 antibodies are complex populations that are not solely helper/ inducer and suppressor/cytotoxic populations, respectively. The studies from other laboratories (36) (37) (38) (44) have shown structural differences between the antigen detected by anti-Tac on certain ATL cells as compared with Tac receptors on activated normal T cells also supporting the view that ATL is associated with aberrant receptors for TCGF and that an abnormality in this receptor may play a role in growth of these leukemic cells.
